<DOC>
	<DOCNO>NCT01063257</DOCNO>
	<brief_summary>This study aim determine maximal tolerate dose ( MTD ) dose limit toxicity ( DLTs ) low dose IV clofarabine MDS patient treatment failure azacitidine .</brief_summary>
	<brief_title>Clofarabine High Risk Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>The study open-label , 3+3 dose-escalation , phase I/II study.The duration enrollment phase I study 12 month . Fourteen patient enrol RD use select dose cohort , enrollment period 12 month . Each patient may receive 8 course , every 4 8 week D1-D5 schedule every day D1 D10 . Each patient follow 24 month . Primary endpoint phase I part : - To determine maximal tolerate dose ( MTD ) dose limit toxicity ( DLTs ) increase dos IV clofarabine administer either daily D1 D5 28 56 day-course every day D1 D10 28 56 day-course . Secondary endpoint : - To determine response rate , defined 2006 modify IWG criterion , associate two different dose schedule clofarabine patient high-risk MDS AML patient less 30 % marrow blast ( RAEB-T FAB MDS classification ) , previously treat azacitidine without erythroid response 6 cycle azacitidine . - To evaluate response duration , time IPSS progression , loss RBC transfusion independence patient . - To evaluate hospitalization duration , rate rehospitalization non-hematological toxicity , severe bleed febrile neutropenia . If treatment feasible study extend phase II part . Study Objectives : Primary endpoint : - To confirm safety hematological toxicity 14 additional patient . Secondary endpoint - To evaluate response duration , time IPSS progression , loss RBC transfusion independence patient . - To evaluate hospitalization duration , rate rehospitalization non hematological toxicity , severe bleed febrile neutropenia . - To determine response rate define 2006 modify IWG criterion .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>Patients age 18 year MDS accord FAB classification intermediate2 high IPSS risk score , CMML ( WBC &lt; 13 x 109/L bone marrow blast &gt; 10 % ) accord WHO classification , AML accord WHO classification le 30 % bone marrow blast ( RAEBT accord FAB MDS classification AML accord WHO classification 30 % bone marrow blast precede proven MDS phase . Patients previously treat azacitidine ( Vidaza® ) proven progression , stable 6 course ongoing transfusion dependent anemia ( &gt; 4 RBC unit 8 week precede inclusion ( erythroid response IWG 2006 criterion reduction least 4 RBC unit 8 week ) . Previous biological target therapy MDS AML allow stop 1 month inclusion . ECOG PS ≤ 2 . Adequate renal liver function : i.e . Serum creatinine &lt; 110 microM men 90 microM woman . If plasma creatinine level &lt; 90 110 microM , estimate glomerular filtration rate ( GFR ) must &lt; 50 mL/min/1.73 m2 calculate Modification Diet Renal Disease ( MDRD ) equation Predicted GFR ( mL/min/1.73 m2 ) = 32788 x ( plasma creatinine level ( microM ) 1.154 x ( age year ) 0.023 x ( 0.742 patient female ) x ( 1.212 patient African American ) Bilirubin &lt; 1.5 x ULN , ( except increase unconjugated bilirubin due dyserythropoiesis ) . Aspartate transaminase ( AST ) /alanine transaminase ( ALT ) &lt; 2.5 × ULN Alkaline phosphatase &lt; 2.5 × ULN . Absence pregnancy lactation female patient ( Female patient childbearing potential must negative serum pregnancy test within 2 week prior enrollment ) . Male female patient must use effective contraceptive method study minimum 6 month study treatment . Provided sign write informed consent . Capable understanding investigational nature , potential risk benefit study , able provide valid inform consent . Patients AML bone marrow blast count 2030 % , candidate intensive AML type chemotherapy . Known hypersensitivity clofarabine excipients . Concomitant malignant disease . Active uncontrolled infection ( define exhibit ongoing signs/symptoms related infection without improvement , despite appropriate antibiotic treatment ) . Concomitant severe cardiovascular disease , i.e . congestive heart failure ( NYHA grade &gt; 3 ) . Any significant concurrent disease , illness , psychiatric disorder would compromise patient safety compliance , interfere consent , study participation , follow , interpretation study result . No affiliation national insurance scheme directly equivalent system . Chemotherapy , radiation therapy , immunotherapy specify protocol . Use investigational agent within 30 day anticancer therapy within 2 week study entry exception hydroxyurea . The patient must recover acute toxicity previous therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Myelodysplastic Syndrome</keyword>
</DOC>